The specific pharmacological response evoked by a nicotinic acetylcholine receptor (nAChR)
Discussion

Nicotine Agonist or Antagonist?
The exploration of the actions of the tobacco alkaloid nicotine and the initial concept of nicotinic receptors has continued for well over 100 years. Despite the wealth of published literature that is now available, the pharmacology of nicotine remains to be fully elucidated, and depending on the system studied the drug can evoke responses that are complex, unpredictable, and difficult to interpret. Although traditionally described as a receptor agonist, the net effect of nicotine (i.e., agonist or functional antagonist) could depend on several factors such as the drug dose or concentration, the length of the time of exposure, and the affinity state of the receptor (reviewed, Rowell and Duggan, 1998) . The concept that the CNS effects of nicotine are due to its "agonist" effects at nicotinic acetylcholine receptors (nAChRs) and the subsequent increases in the release of neurotransmitters (as has been suggested many times) is probably overly simplistic, since in a number of settings, nicotine and nAChR antagonists can have very similar physiologic effects. For example, the nAChR antagonists d-tubocurarine and α-bungarotoxin have been observed to produce neuronal excitatory responses (i.e., increased population spikes) in rodent hippocampal slices that were quantitatively similar to those produced by nicotine (Ropert and Krnjevic, 1982) . Also, both nicotine and the α7 nAChR antagonist methyllycaconitine enhanced long-term potentiation after their application to GABA-containing neurons in the CA1 region of the hippocampus (Fujii et al., 2000) . Intrahypothalamic injection of d-tubocurarine was reported to evoke excitatory behavioral responses (i.e., fear and escape reactions) in rats (Decsi and Karmos-Varszegi, 1969; Buccafusco and Brezenoff, 1980) in a fashion similar to carbachol.
Moreover, both nicotine and mecamylamine increased serotonin release in rat dorsal hippocampal slices (Kenny et al., 2000) ; and in guinea pig striatum mecamylamine and the high-affinity This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on November 20, 2008 as DOI: 10.1124 at ASPET Journals on November 5, 2016 jpet.aspetjournals.org Downloaded from antagonist, dihydro-β-erythroidin, exerted effects similar to nicotine on dopamine release under conditions of phasic and tonic activity (Rice and Cragg, 2004) . In studies of receptor regulation, the chronic exposure to either nicotine or to nAChR antagonists, in vivo, has revealed similarities of action. For example, chronic administration of nicotine or mecamylamine to rats increased the expression of [ 3 H]-nicotine binding sites in frontal cortex (Abdulla et al., 1996) and chronic exposure to nicotine or mecamylamine increased the expression of cell surface NGF receptors in PC-12 cells (Terry and Clarke, 1994) .
At relatively high doses mecamylamine is well documented to impair cognition across multiple domains. In the lower dose range, mecamylamine has been reported to improve memory-related task performance similar to nicotine. For example, μg/kg doses of nicotine and mecamylamine each have been observed to enhance delayed matching to sample (DMTS) accuracy in monkeys (Buccafusco and Jackson 1991; Terry et al., 1999) and to improve the performance by rats of a delayed stimulus discrimination task (Terry et al., 1999) . Also in rats, mecamylamine dose-dependently improved working memory in a T-maze alternation task when 30 second intervals were imposed between stimulus and response (Moran, 1993) . Supporting data also are derived from studies in which chronic administration of either nicotine or mecamylamine was reported to improve performance in a in a radial arm maze task, and in a Tmaze alternation task (see, Levin et al., 1997) .
The Case for Nicotinic Receptor Desensitization
The complex pharmacology of nicotine and the perplexing pharmacological similarities between nicotine and low doses/concentrations of the nAChR antagonists described above could This article has not been copyedited and formatted. The final version may differ from this version. Like nicotine, the ability of cotinine, nicotine's primary metabolite, to induce the release of dopamine in vitro occurs at much higher concentrations than those present in the brains of smokers (O'Leary et al., 2008) . Cotinine has relevance to nicotine's actions because the metabolite has been reported to induce a variety of behavioral responses in animals including positive effects on information processing and cognitive function (Terry et al. 2005) . Because brain nicotine and cotinine concentrations after smoking are not sufficient to induce neurotransmitter release, both compounds could mediate their behavioral actions through nAChR desensitization. nAChR desensitization, rather than receptor activation, is rapidly gaining attention as a major contributor to the behavioral actions of nicotine (Picciotto et al., 2008 suggests that the latter are related more to the desensitized state as occurs in binding studies.
However, even during periods of receptor desensitization nicotinic receptor-mediated activity is far from completely eliminated (Grady et al., 1997) . This situation could help explain the need for continuous exposure to nicotine by cells in culture in order for the drug to induce a cytoprotective action (Jonnala et al., 2002) . Clearly in such situations nAChRs exist primarily in the desensitized-high affinity state. This situation helps regulate calcium influx through nAChR channels thus maintaining intracellular calcium levels that are pro-survival. In tissue culture the question arises as to how incubation of cells with low concentrations of nAChR antagonists like mecamylamine results in cytoprotection. One possibility is that incomplete antagonism could mimic agonist-induced desensitization which is also a form of incomplete antagonism. Low concentrations of mecamylamine could limit the endogenous toxicity mediated through α7nAChRs (see, Lukas et al., 2001) . Thus it is possible to envision a mechanism characterized by partial inhibition of nAChR function that could explain the ability of agonists and antagonists of the receptor to evoke largely similar pharmacological responses.
In cultured cells, particularly those that are differentiated, both acetylcholine and choline can serve as agonists for nAChRs. Choline is a low potency, but full agonist of α7nAChRs. It is perhaps easier to conceive that desensitization of α7 nAChRs in vivo could induce an agonist-like behavioral response (e.g., improvement in working memory) through the process of disinhibition. The α7 subtype is well expressed in the hippocampus, which receives considerable innervation from cholinergic afferents arising from the medial septum. Presynaptic and postsynaptic nAChRs have been identified in layer CA1 where they are expressed by local circuit neurons. Activation of these cells by nAChRs can result both in inhibition and disinhibition of pyramidal cells (Frazier et al., 2002) . Specifically nAChR activation has been reported to activate GABAergic activity in hippocampal CA1 stratum radiatum interneurons (Mok and Kew, 2006) . Whereas brief exposure to a very high concentration of agonist can produce excitatory currents in hippocampal interneurons, prolonged application leads to desensitization. Moreover, desensitization of nAChRs expressed on hippocampal hilar neurons is produced by 250 fold lower concentrations of choline than is required for receptor activation (Frazier et al., 2002) . Therefore under conditions in which relatively low doses of nicotine or other agonists are administered, e.g., to produce an improvement in working memory, JPET #145292 PiP 9 might be more difficult to explain with this simplistic model. The ability of high doses of mecamylamine to enhance GABA release (a potential mechanism for its amnestic actions) has not been reported; however, the antagonist has been reported to induce the release of serotonin from hippocampal synaptosomes in vitro (Kenny et al., 2000) . Alternatively nicotinic agonists also induce the release of glutamate, facilitating long-term potentiation (Welsby et al. 2006) , and the higher dose range of antagonists like mecamylamine could reduce glutamatergic transmission (O'Dell and Christensen, 1988) . One example involves the finding that α7 nAChR agonists induce a pattern of opposing responses mediated by GABAergic stratum radiatum interneurons in the CA1 region of the hippocampus (Wanaverbecq et al., 2007) . Agonists were shown to induce GABA release from target cells, but simultaneously they depressed inhibitory currents mediated postsynaptically by GABA A receptors. It remains to be determined whether nAChR antagonists differentially inhibit these two cellular events; however, very low concentrations (maximally 10 nM) of methyllycaconitine blocked nAChR agonist-induced inhibition of GABA A -mediated currents (Wanaverbecq et al., 2007) . This degree of sensitivity to α7 nAChR blockade could explain the agonist-like action of low doses of mecamylamine.
In summary, the discussion thus far makes a case for focusing new drug development on compounds that desensitize nAChRs. In fact, almost all of the new agonists developed in the past two decades have the potential to desensitize nAChRs; however, most of these accomplish this action by first activating the receptor at the orthosteric site. The problem with this approach is that it has not generated very highly subtype selective ligands, and many compounds share side effect profiles with nicotine. Targeting allosteric sites on nAChRs could be one approach to potentially improve subtype selectivity. But if the idea is to induce desensitization without activation, a new type of compound is warranted.
This article has not been copyedited and formatted. The final version may differ from this version. The Relevance of Allosteric Binding Targets (Silent Desensitizers)
Positive allosteric modulators, defined as compounds that facilitate endogenous neurotransmission without directly stimulating the target receptors, have been known for ligandgated ion channel receptors, including nAChRs, for several years (see, Albuquerque et al., 2001 ).
Very few such compounds have been characterized in vivo. In addition to its property as an inhibitor of acetylcholinesterase, the Alzheimer's drug galantamine has been suggested to act as a positive allosteric modulator of nAChRs (see, Coyle et al., 2007) . However, galantamine's allosteric effects in vivo will always be overshadowed by its anti-cholinesterase activity. A more relevant proof of concept is derived from studies with the compound PNU-120596 (1-(5-chloro- (Hurst et al., 2005) . PNU-120596 inhibited the ability of amphetamine to suppress auditory gating as measured by auditory-evoked potential in anesthetized rats. This property of the compound suggests its potential for use in schizophrenia, a disorder characterized by auditory gating deficits. The in vitro, effects of PNU-120596 were shown to be mediated by α7 nAChRs. However, positive allosteric modulators like PNU-120596 enable nicotinic cholinergic neurotransmission in large part by preventing desensitization, and on their own they cannot desensitize nAChRs.
2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea) which has been demonstrated to act as a positive allosteric modulator of nAChRs both in vitro and in vivo
If desensitization of nAChRs is to be considered a viable drug target, compounds will need to be developed that simply desensitize the receptor without activation -so-called "silent Despite its affinity for the orthosteric site of the receptor, the compound evoked no agonist like effect; but pretreatment for as little as 10 minutes with the drug inhibited the subsequent response ( 86 Rb + release) evoked by nicotine. In this regard the compound was 50 fold more potent than the competitive antagonist dihydro-β-erythroidin. The concept is that a silent desensitizer traps the receptor in a high-affinity, desensitized state. Sazetidine-A also exhibits certain nicotinic-like pharmacological responses. For example, the compound can substitute in a nicotine/saline discrimination task, and it exhibits epibatidine-like antinociceptive activity (see, Zwart et al., 2008) . Based on the premise put forth in this review, we would surmise that these agonist-like responses were a direct result of desensitization. However, a more recent study with the compound indicates that sazetidine-A induces the release of dopamine from striatal slices, an effect mediated through α4β2 and α6-containing subtypes of nAChRs (Zwart et al., 2008) . Of particular interest was the finding that the precise stoichiometry of the α4β2 receptor was important for determining the potency of sazetidine-A. Thus it remains to be determined which, if any, of the compound's actions could be attributed to silent desensitization.
Analogs of Choline
We synthesized a series of about 50 analogs of choline with the expectation that these compounds would serve as selective agonists for the α7 subtype of nAChRs (Buccafusco 2004 ).
Most of the compounds were created as tertiary amine analogs so that they would have drugable characteristics without the need to serve as substrates for the choline transporters. Our initial examination of these compounds demonstrated varying potencies and efficacies in an assay for cytoprotection (Buccafusco et al., 2005) . The compounds did not interact with choline Carolina at Chapel Hill). There were no significant interactions in the screen of 40 potential drug targets except perhaps between JAY2-22-33 and H3 histamine receptors, but this interaction has not been confirmed. So we were left with a series of interesting compounds with significant therapeutic potential, but with no mechanism of action to consider.
Fortunately we were able to derive some insight from our parallel studies of cotinine, which seemed to present the same conundrums as did the choline analogs. As mentioned above, cotinine exhibits several nicotine-like properties (Buccafusco and Terry, 2003) : (1) In the rat, the motor response to acoustic startle can be inhibited by the presentation of a low-level acoustic prepulse presented just in advance of the high-level acoustic pulse, thereby providing a measure capable of evoking partial nAChR desensitization (Briggs et al., 1999; Vainio and Tuominen, 2001 ). We recently confirmed the ability of cotinine to partially desensitize ganglionic nicotinic receptors in vivo with no apparent activation of the receptor. In this paradigm, both nicotine and cotinine readily desensitized nAChRs to the stimulus properties of the ganglionic, nicotinic agonist dimethylphenylpiperazinium (DMPP). Acute injection of DMPP induced a dose-related increase mean arterial blood pressure in freely moving rats. In this regard, cotinine produced no significant effects on blood pressure of its own at up to 13 times the dose of nicotine (Buccafusco et el., 2007b) .
Thus it was no great leap of insight to then evaluate JWB1-84-1 and JWB2-22-33 in the DMPP paradigm. Adult rats were instrumented to allow the continuous recording of blood pressure via previously implanted aortic catheters, and for the intravenous infusion of drug solutions through a catheter implanted in the jugular vein (for experimental details see Buccafusco et al., 2007b) . Test compound or vehicle (sterile, heparinized saline) was infused over a 20 minute period, followed by a 5 minute rest interval during which pre-injection MAPs were obtained. At the end of the interval 40 μg/kg DMPP was injected as a bolus to produce a short-lived (about 10 min) but dramatic (up to 40 mmHg) increase in MAP. Figure 1A response that was nearly as effective, but was observable across a wider dose range.
All four compounds were studied in the same DMTS task in macaques (Buccafusco et al., 1999; Terry et al., 2005; Sood et al., 2007 ; the data for JWB2-22-33 are unpublished). All four compounds significantly improved task accuracy with predominant effects during long delay intervals (representing retention/retrieval components of working memory). Figure 1C presents the increase in task accuracy represented as the % increase from vehicle produced by each compound in the primate task plotted as a function of the ability to desensitize ganglionic nAChRs in the rat DMPP study (i.e., the data derived from Figure 1B) . Surprisingly, there was a very high degree of correlation between the two. Recognizing that we are working only with 4 data points, the high degree of correlation between these two disparate responses to our test compounds at least suggests the possibility that efficacy for desensitization plays a role in the positive mnemonic responses produced by these compounds. The hypothesis is modeled in Figure 2 . It presumes that there is a direct relationship between the three systems: acetylcholine activates nicotinic receptors on GABA interneurons in the hippocampus which in turn leads to inhibition of primary hippocampal glutamate neurons. This situation would keep activation of glutamate neurons under check during normal non-learning or non-remembering situations.
When acetylcholine is over-activated (as with cholinesterase inhibitors) or when a nAChR agonist is administered, the first response is further activation of the GABA interneuron. But because α7
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Clearly the situation is more complicated. However, the model provides a basis for new drug discovery. Not only do allosteric nAChR compounds exhibit subtype specificity, but they could potentially be specific for various combinations and stoichiometries of subunits (Zwart et al., 2008) . This is a double edge sword. High selectivity opens the door to specificity of action with reduced side effects. However, greater knowledge of the true expression and stoichiometry of human nAChR subtypes will be required. Such uncertainty enhances the need for animal testing, and particularly for studies of efficacy in non-human primates which have greater translational value in this regard than rodents. Low side effect profiles also could be characteristic of silent desensitizers which fail to first activate ligand-gated ion channel receptors. With the amyloid hypothesis in doubt (Holmes et al., 2008) , the search for compounds that can both improve cognition and produce neuroprotection, possibly slowing the disease process, becomes paramount.
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